¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tumor necrosis factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • factor XIIa
    Á¦ XIIa ÀÎÀÚ
  • factor XIa
    Á¦ XIa ÀÎÀÚ
  • factor Xa
    Á¦ Xa ÀÎÀÚ
  • factor deficiency
    Á¦ÀÎÀÚ°áÇÌÁõ(ð¯ì×í­ÌÀù¹ñø).
  • factor ii(prothrombin)
    Á¦2ÀÎÀÚ(ÇÁ·ÎÆ®·Òºó)
  • factor ix deficiency
    Á¦9ÀÎÀÚ °áÇÌ(Áõ)
  • factor theory
    ¿äÀÎÀÌ·Ð(é©ì×ìµÖå)
  • factor vii
    Á¦7ÀÎÀÚ
  • factor viii deficiency
    Á¦8ÀÎÀÚ °áÇÌ(Áõ)
  • factor viii-vwf complex deficiency
    Á¦8-vWF º¹ÇÕ °áÇÇ
  • factor x
    Á¦10ÀÎÀÚ
  • factor xa
    Á¦10 aÀÎÀÚ
  • factor xiia
    Á¦12 aÀÎÀÚ
  • factor, chemotactic
    È­ÇÐÁÖ¼ºÀÎÀÚ, ÁÖÈ­¼ºÀÎÀÚ
  • factor, macrophage migration inhibition
    ´ë½Ä¼¼Æ÷ À¯ÁÖÀúÁöÀÎÀÚ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 17
IAN idiopathic aseptic necrosis; indole acetonitrile
IBSN infantile bilateral striated necrosis
INB internuclear bridging; ischemic necrosis of bone
IPN infantile polyarteritis nodosa; infectious pancreatic necrosis [of trout]; intern progress note; int...
LN Lesch-Nyhan [syndrome]; lipoid nephrosis; Lisch nodule; low necrosis; lupus nephritis; lymph node
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 17
HTCA Human Tumor Cloning Assay
HTCA Human Tumor Clonogenic Assay
HTCFA Human Tumor Colony Forming Assay
IMT Inflammatory myofibroblastic tumor
IPMT Intraductal papillary mucinous tumor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • migration inhibitory factor test
    À¯ÁÖ ÀúÁö ÀÎÀÚ ½ÃÇè
    ƯÀÌ Ç׿ø¿¡ ¹ÝÀÀÇÏ¿© ¸²ÇÁ±¸°¡ MIF¸¦ »ý¼ºÇÏ´Â µ¥ ´ëÇÑ »ýüÀÇ ½ÃÇè¹ýÀ¸·Î ¼¼Æ÷ ¸Å°³ ¸é¿ªÀ» Æò°¡ÇÏ´Â µ¥ »ç¿ëÇÑ´Ù. ÀϺΠ¸é¿ª °áÇÌ Áúº´, Áï DiGeorge ÁõÈıº, Wiskott-Aldrich ÁõÈıº, Hodgkin º´¿¡¼­´Â MIF°¡ »ý¼ºµÇÁö ¾Ê´Â´Ù.
  • milk factor
    ¸ðÀ¯ ÀÎÀÚ
  • monocytosis-producing factor
    ´ÜÇÙ±¸ Áõ°¡Áõ À¯¹ß ÀÎÀÚ
  • multiple factor
    ´Ù¹ß¼º ÀÎÀÚ
  • myocardial depressant factor
    ½É±Ù ¾ïÁ¦ ÀÎÀÚ
  • natural moistening factor
    ÀÚ¿¬ º¸½À ÀÎÀÚ
  • negative cognitive factor
    ºÎÁ¤ÀûÀÎ ÀÎ½Ä ¿äÀεé
  • nutritional factor
    ¿µ¾ç ÀÎÀÚ
  • pathophysiologic factor
    º´Å »ý¸®ÇÐÀû ¿äÀÎ
  • pellagra preventive factor
    Æç¶ó±×¶ó ¿¹¹æ ÀÎÀÚ
  • platelet aggragating factor
    Ç÷¼ÒÆÇ ÀÀÁý ¿ä¼Ò, Ç÷¼ÒÆÇ ¾ÇÈ­ ÀÎÀÚ, Ç÷¼ÒÆÇ ¾ÇÈ­ ¿äÀÎ
    ¸é¿ª ±Û·ÎºÎ¸° E¿¡ °¨±¤µÈ È£¿°±â±¸¿¡¼­ÀÇ Ç׿ø ¹ÝÀÀ¿¡ ÀÇÇØ Ç÷¾× ³»¿¡ »ý¼ºµÈ ¹°Áú·Î¼­ Ç÷¼ÒÆÇÀ» ÀÀÁý½Ã۸ç, ¿°ÁõÀ» À¯¹ß½ÃŲ´Ù.
  • platelet-activating factor
    Ç÷¼ÒÆÇ Ȱ¼º ÀÎÀÚ
  • predisposing factor
    ¼ÒÀÎ, Áúº´ ¼ÒÁú
    ÁúȯÀ̳ª Àå¾Ö¸¦ À¯¹ß½Ãų À§Ç輺À» Áõ°¡½ÃŰ´Â ¿ä¼Ò.
  • psychogenic factor
    Á¤½ÅÀû ¿ä¼Ò, ½ÉÀμº ¿ä¼Ò
  • psychosocial factor
    »çȸ Á¤½ÅÀû ¿äÀÎ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
decay accelerating factor <biochemistry, protein> Plasma protein that regulates complement cascade by blocking the formation of the C3bBb complex (the C3 convertase of the alternate pathway).
Widely distributed in tissues but deficient in paroxysmal nocturnal haemoglobinuria.
(18 Nov 1997)
suppressor factor <immunology> Factors released by T suppressor cells.
See: suppressor mutation, ochre suppressor, opal suppressor.
(19 Jan 1998)
diabetogenic factor Rarely used term for a factor in crude extracts of the anterior lobe of the hypophysis that produces degenerative changes in the islet cells of the pancreas and causes permanent diabetes.
(05 Mar 2000)
diffusing factor <enzyme> Enzyme that degrades hyaluronic acid, found in lysosomes.
(18 Nov 1997)
direct lytic factor of cobra venom A polypeptide of 62 residues; action on cells is similar to that of melittin in that it promotes disruption of membranes; used as an investigational antirheumatic agent.
Synonym: cobra toxin, direct lytic factor of cobra venom.
(05 Mar 2000)
Duran-Reynals permeability factor <enzyme> Enzyme that degrades hyaluronic acid, found in lysosomes.
(18 Nov 1997)
duty factor <radiobiology> Ratio of the duration of time when a system is actually operating to the total time for a complete cycle of the system. For example: if a tokamak experiment runs for 5 seconds and then sits for 500 seconds while the power supplies are recharged, then the duty factor is 1%. Similar to capacity factor for powerplants.
Synonym: duty cycle.
(09 Oct 1997)
q-factor <radiobiology> Ratio of power produced by fusion to power put into the reactor to heat the plasma and drive the magnetic fields.
Q = 1 is the definition of scientific breakeven, where power out = power in. Economical fusion will require Q significantly greater than 1. Fortunately Q increases dramatically as the plasma parameters approach the Lawson criterion for ignition. Power to drive the magnetic fields is frequently ignored in discussions of Q, with the justification that a steady-state, continuous-output fusion reactor will have superconducting magnet coils.
(15 Dec 1997)
quality factor <radiobiology> (Q) A multiplying factor used with absorbed dose to convert to dose equivalent and therefore to express the radiation's effectiveness in causing biological effects.
(16 Dec 1997)
inhibition factor <growth factor> A soluble, nondialysable factor that is produced by sensitised lymphocytes following exposure to a specific antigen. It inhibits macrophage migration and causes adherence.
It was originally defined on the basis of inhibition of emigration of mononuclear cells from capillary (haematocrit) tubes, more recently a 13 kD protein with migration inhibitory activity has been isolated.
Acronym: MIF
Synonym: inhibition factor.
(22 Sep 2002)
initiation factor One of several soluble proteins involved in the initiation of protein or RNA synthesis.
(05 Mar 2000)
insulin activating factor <chemical> Activates insulin gene transcription in pancreatic beta cells.
Synonym: insaf
(05 Dec 1998)
insulin-antagonizing factor A principle in extracts of the anterior lobe of the hypophysis that raises the blood sugar and antagonises the action of insulin; purified pituitary growth hormone produces an identical effect.
Synonym: insulin-antagonizing factor.
(05 Mar 2000)
insulin like growth factor <growth factor> Insulin like growth factors I and II are polypeptides with considerable sequence similarity to insulin.
They are capable of eliciting the same biological responses, including mitogenesis in cell culture. On the cell surface, there are two types of insulin like growth factor receptor, one of which closely resembles the insulin receptor (which is also present).
Insulin like growth factor I = somatomedin A = somatomedin C
Insulin like growth factor II = MSA (Multiplication stimulating activity).
Insulin like growth factor 1 is released from the liver in response to growth hormone.
Acronym: IGF
(18 Nov 1997)
insulin-like growth-factor binding protein 1 One of the six homologous proteins that specifically bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions. The function of this protein is not completely defined. However, several studies demonstrate that it inhibits igf binding to cell surface receptors and thereby inhibits igf-mediated mitogenic and cell metabolic actions. (proc soc exp biol med 1993;204(1):4-29)
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 17
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 17
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 17
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 17
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 17
ÅëÇÕ°Ë»ö ¿Ï·á